EPV-CoV-19 is a peptide-based, epitope-driven vaccine that aims to drive a T cell-mediated immune response, creating a sort of "body armor" for users, according to the company.

Under the licensing agreement, EVT will use its vaccine platform and fundraising experience to advance EPV-CoV-19. The company is progressing to a clinical trial of the vaccine since it already received a positive preinvestigational new drug response from the U.S. Food and Drug Administration. Also, peptide production has started, and the investigational new drug application is being prepared.

Recently, EVT reorganized its executive team in preparation for the agreement and is raising $3 million to support the new program.

Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate,...

Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...

RNAimmune gets $2.35M for mRNA therapeutics, vaccines
RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and...

Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...

Intravacc, EpiVax partner for COVID-19 vaccine
Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer...